E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
patients with newly diagnosed (first episode) extensive chronic Graft versus Host Disease (cGvHD) post allogeneic transplantation for any primary diagnosis |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 7 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10018651 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To improve remission rates of chronic GvHD with cyclosporine A+ prednisone+ Myfortic® (CsA+PDN+MPA) combination as compared to the reference treatment with CsA+PDN |
|
E.2.2 | Secondary objectives of the trial |
1) To spare patients from long-term use of corticosteroids (and of their long-term side effects)
2) To decrease transplant-related morbidity (infectious and non-infectious)
3) To study time to cessation of any immunosuppressive therapy
4) To test prospectively the NIH severity index for chronic GvHD |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Age 18 – 60 2) Any primary diagnosis requiring treatment by hematopoietic stem cell transplantation (HSCT) 3) Recipient of a single allogeneic stem cell transplant (bone marrow or peripheral blood stem cells, or cord blood) minimum 80 days ago 4) Transplant from a related or unrelated donor 5) Conditioning regimen: Myeloablative or non-myeloablative 6) Patients with a 1st episode of extensive chronic GvHD, without recurrent disease 7) The diagnosis of chronic GvHD as defined by the NIH diagnostic and scoring system 8) Receiving a standard prophylaxis regimen for acute GvHD: CsA alone, CsA plus methotrexate or CsA+MMF for NMA, or a T-cell depleted transplantation 9) Negative pregnancy test in females of child-bearing potential – see section 5.4 10) Written informed patient consent prior to randomisation |
|
E.4 | Principal exclusion criteria |
1) Age less than 18 or over 60 years old 2) GvHD prophylaxis by tacrolimus plus methotroxate 3) Delayed onset acute GvHD following non-myeloablative conditioning or donor lymphocyte infusion 4) Second allogeneic stem cell transplant 5) Not the first episode of chronic GvHD needing systemic immunosuppressive therapy 6) Limited chronic GvHD (Seattle criteria) 7) MMF used to prevent or treat GvHD in the previous 4 weeks 8) Neutropenia 9) Uncontrolled systemic infection with an increased risk of the patient’s death within 1 week of randomization 10) If the patient has significant medical or psychosocial problems or unstable disease status 11) Pregnant or lactating females 12) Patients and/or female partners of male patients not using methods of birth control as defined in section 5.4 of Protocol 13) Known hypersensitivity to mycophonolic acid 14) No simultaneous participation in other chronic GvHD treatment trials allowed |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1) Efficacy success, defined as the response rate (Complete Remission or Partial Remission of chronic GvHD) at 1 year post randomization, with no secondary systemic therapy at any time.
2) the requirement for secondary systemic therapy at 1 year post randomization
3) incidence of recurrent malignancy at 1 year post randomization (of the original diagnosis requiring transplantation) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 38 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
last visit last patient (1 year follow-up visit) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |